News

Three people stood in front of hospital building, from left to right: Matthias Zilbauer, Claire Glemas, Robert Heuschkel.

Zilbauer Group recognised for outstanding paediatric involvement and engagement efforts

31 May 2023

The Royal College of Paediatrics and Child Health (RCPCH) and National Institute of Health Research (NIHR) have awarded their 2023 Paediatric Involvement and Engagement in Research Prize to the research group led by Dr Matthias Zilbauer.

Wellcome announce funding for Cambridge Stem Cell Institute as new Discovery Research Platform for Tissue Scale Biology

4 May 2023

Discovery Research Platforms will bring together researchers, teams and networks of collaborators to develop new tools, knowledge and capabilities, with the hope of accelerating progress for the benefit of the wider global research community. Wellcome selected eight platforms to fund a total of £73 million, two of which will be hosted at the University of Cambridge.

New SCI-TIF members gather for inaugural networking dinner

25 April 2023

Last night, 24 April 2023, the Cambridge Stem Cell Institute Technology & Innovation Forum (SCI-TIF ) gather with their new members for an inaugural networking dinner to mark the start of the forum. Initiated with a launch event last November, this forum aims to unite scientists in industry and academia based on a...

Applications now open for Professorship in Stem Cell Medicine

3 March 2023

The Wellcome-MRC Cambridge Stem Cell Institute and the School of Clinical Medicine are pleased to announce that applications are now welcome for the Professorship of Stem Cell Medicine. We are seeking candidates who have: the vision, leadership experience and enthusiasm to develop and maintain a leading research presence...

Dr Elisa Laurenti and Dr Daniel Hodson awarded ERC Grants

7 February 2023

Two CSCI Group Leaders are among the eight researchers from the University of Cambridge who were awarded European Research Council (ERC) Consolidator Grants last week. Dr Elisa Laurenti and Dr Daniel Hodson were selected from over 2,000 applicants for their research conducted at the Wellcome-MRC Cambridge Stem Cell...

Dr Harry Bulstrode joins team of Principal Investigators

CSCI Welcomes Dr Harry Bulstrode as new Group Leader

30 January 2023

Dr Harry Bulstrode joins us this week (1 February) as a Principal Investigator researching n eural stem cells in relation to development, regeneration and cancer. Dr Bulstrode joins us most recently from the Francis Crick Institute, where he studied glioma stem cell biology and the tumour microenvironment in malignant...

Apply now for Stem Cells IRC Small Grants

16 January 2023

The Stem Cells Interdisciplinary Research Centre (IRC) is currently inviting postgraduate researchers and postdoctoral research fellows to submit applications for research funding and training, rooted in stem cell research that fosters integration along disciplines. Eligibility The scheme is open to all postgraduate...

CSCI Scientists Sinha, Karadottir, and Sampaziotis. Credit: Alun Callender

CSCI scientists on regenerative medicine research

9 January 2023

Dr Thóra Káradóttir , Professor Andrew McCaskie , Dr Fotios Sampaziotis , and Professor Sanjay Sinha of the Wellcome-MRC Cambridge Stem Cell Institute (CSCI) were recently interviewed in CAM Magazine’s recent feature on regenerative medicine. Discussing their work on hearts, livers, joints, and brains, using cutting-edge...

CSCI welcomes new cohort of postgraduate students

8 December 2022

A total of 26 new Postgraduate students started at CSCI in October 2022, under the supervision of 11 different PIs within the Institute. These students are on a variety of PhD and Masters programmes, and are based in the following labs: Wellcome MRes + PhD Programme (currently doing rotations): 6 students CCMR MRes + PhD...

Off-patent liver disease drug could prevent COVID-19 infection

5 December 2022

Cambridge scientists from the Sampaziotis lab show that a widely used drug to treat liver disease can prevent COVID-19 infection or reduce disease severity Cambridge Stem Cell Institute scientists have identified an off-patent drug that can be repurposed to prevent COVID-19 – and may be capable of protecting against future...